title: The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
abstract: The objective of this study was to explore the relationship between gefitinib exposure and clinical outcome in gefitinib-treated patients with advanced non-small cell lung cancer. Thirty patients participated in this pharmacokinetic study and received 250-mg oral doses of gefitinib once daily. Blood samples were collected before dosing and on days 7, 14, 21, and 28. The plasma concentrations of gefitinib were evaluated using a validated high-performance liquid chromatographic method with tandem mass spectrometric detection. Univariate and multivariate analyses were performed to determine predictive factors for response and survival of patients. EGFR mutations were analyzed retrospectively. Median survival time (MST) was 9.97 months (95%CI 2.79-17.14 months). The geometric mean trough gefitinib plasma concentration (Cminss was 266 ng/ml (range 94-538 ng/ml). In the multivariate analysis, only skin rash was associated with gefitinib-induced disease control (P=0.017); Adenocarcinoma, skin rash, and 'high' Cminss (Cminss≥200 ng/ml) were independently associated with overall survival (P=0.004, 0.028,0.007, respectively). MST of EGFR wild-type patients with 'high' Cminsswas longer than that with 'low' Cminss (P=0.002). Our study results show that pharmacokinetic variability may also account for the different outcomes following treatment with gefitinib for patients with wild-type EGFR. Further studies are needed to confirm these results.
authors.affiliation: State Key Laboratory of Oncology in South China and Department of Medical Oncology, Cancer Centre, Sun Yat-Sen University, 651 Dong Feng Road East, Guangzhou, 510060, People's Republic of China.
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Zhao
authors.forename: Su
authors.initials: S
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hong-Yun
authors.initials: HY
authors.lastname: Zhao
authors.forename: Hai
authors.initials: H
authors.lastname: Liao
authors.forename: Ying
authors.initials: Y
authors.lastname: Guo
authors.forename: Yan-Xia
authors.initials: YX
authors.lastname: Shi
authors.forename: Wei
authors.initials: W
authors.lastname: Jiang
authors.forename: Cong
authors.initials: C
authors.lastname: Xue
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D002851:Chromatography, High Pressure Liquid; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D053719:Tandem Mass Spectrometry; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib
references.citation: J Natl Cancer Inst. 2006 Dec 6;98(23):1714-23
references.pmid: 17148773
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2493-501
references.pmid: 15710947
references.citation: Clin Pharmacokinet. 2006;45(6):633-44
references.pmid: 16719544
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3731-7
references.pmid: 17575239
references.citation: J Clin Oncol. 2004 Mar 1;22(5):785-94
references.pmid: 14990633
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Clin Oncol. 2005 Oct 1;23(28):6838-45
references.pmid: 15998906
references.citation: J Clin Oncol. 2004 Mar 1;22(5):777-84
references.pmid: 14990632
references.citation: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references.pmid: 15870435
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71
references.pmid: 16609030
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2653-9
references.pmid: 19414683
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references.pmid: 12409327
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: J Clin Oncol. 2002 Jan 1;20(1):110-24
references.pmid: 11773160
references.citation: J Pharm Biomed Anal. 2002 Jun 20;29(1-2):221-8
references.pmid: 12062681
references.citation: Clin Pharmacokinet. 2005;44(11):1165-77
references.pmid: 16231967
references.citation: J Clin Pharm Ther. 2004 Apr;29(2):95-103
references.pmid: 15068398
references.citation: Clin Pharmacol Ther. 2006 Aug;80(2):136-45
references.pmid: 16890575
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references.pmid: 15741570